On April 11, 2017, the U.S. International Trade Commission (“Commission”) issued a press release announcing their vote to institute an investigation of Certain Intravascular Administration Sets and Components Thereof (Inv. No. 337-TA-1048).
By way of background, this investigation is based on a March 8, 2017 complaint filed by Curlin Medical Inc. of East Aurora, New York; Zevex, Inc. of Salt Lake City, Utah; and Moog Inc. of East Aurora, New York alleging violation of Section 337 by way of unlawful importation into the U.S., selling for importation, and/or selling within the U.S. after importation certain intravascular administration sets and components thereof that infringe one or more claims of U.S. Patent Nos. 6,164,921 and 6,371,732. See our March 17, 2017 post for more details on the complaint.
According to the Notice of Investigation, the Commission has identified Yangzhou WeiDeLi Trade Co., Ltd. of China as the sole respondent in this matter.
Lastly, Chief ALJ Charles E. Bullock issued a notice indicating that he will be the presiding Administrative Law Judge in this matter.